Invitris raises €250K Bridge round
8 May 2023· Munich, Germany· health, biotech, synthetic_biology, b2b, software_hardware, drug_discovery
The funding, designated as 'Stage II Funding,' will enable Invitris to complete its spin-out from the Technical University of Munich (TUM) and further its mission to scale the production of antimicrobial proteins to combat antibiotic resistance, developing towards a GMP-ready process.
Investors
LeadINCATE
About Invitris
Stage
Bridge
Headquarters
Munich, Germany
Founded
2018
Team Size
6–20
Sectors
healthbiotechsynthetic_biologyb2bsoftware_hardwaredrug_discovery